Clinical Trials Sponsored by Topix Pharmaceuticals, Inc

Total 4969 results

Tonix Pharmaceuticals, Inc.

Completed

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RALLY)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Withdrawn

Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

PTSD

Kenya
Tonix Pharmaceuticals, Inc.

Completed

Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.

Terminated

A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients

Primary Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers

Healthy
Tonix Pharmaceuticals, Inc.

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Withdrawn

An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects

Cocaine Intoxication

United States
Tonix Pharmaceuticals, Inc.

Terminated

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD (RECOVERY)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

Dose-Proportionality and Food Effect Study of TNX-102 SL

Healthy Subjects

Canada
Tonix Pharmaceuticals, Inc.

Completed

A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.

Healthy

Canada
Tonix Pharmaceuticals, Inc.

Completed

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients (BESTFIT-OLE)

Primary Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache

Tension-Type Headache

United States
Tonix Pharmaceuticals, Inc.

Completed

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) (BESTFIT)

Primary Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PREVAIL)

COVID-19 | Long COVID | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection | Long Haul COVID

United States
Tonix Pharmaceuticals, Inc.

Completed

A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RELIEF)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD (P306)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Terminated

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia (RE-AFFIRM)

Nervous System Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | Fibromyalgia | Myofascial Pain Syndromes

United States
Tonix Pharmaceuticals, Inc.

Completed

Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

Healthy Subjects

Canada
Tonix Pharmaceuticals, Inc.

Completed

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia (AFFIRM)

Nervous System Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | Fibromyalgia | Myofascial Pain Syndromes

United States
Tonix Pharmaceuticals, Inc.

Completed

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions (P202)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions (AtEase)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.

Completed

Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.

Completed

Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.
Premier

Completed

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine (PREVENTION)

Chronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura Migraine

United States
Tonix Pharmaceuticals, Inc.
Rho, Inc.

Completed

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) (UPLIFT)

Depressive Disorder | Depression | Depressive Symptoms | Depressive Disorder, Major | Depressive Episode | Depression Severe

United States
Yardley Dermatology Associates
Topix Pharmaceuticals, Inc

Terminated

The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol

Acne Vulgaris

United States
Tonix Pharmaceuticals, Inc.
Premier Research Group plc

Terminated

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD (HONOR)

PTSD

United States
Tonix Pharmaceuticals, Inc.
Premier Research Group plc

Terminated

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

PTSD

United States
Tonix Pharmaceuticals, Inc.
Premier Research Group plc

Active, not recruiting

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens (COVID-19 DTH)

Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

United States
Tonix Pharmaceuticals, Inc.
National Institute on Drug Abuse (NIDA); Premier

Not yet recruiting

Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST) (CATALYST)

Cocaine Use | Cocaine Abuse | Cocaine Adverse Reaction | Cocaine Intoxication | Cocaine Toxicity
Englewood Hospital and Medical Center
Topix Pharmaceuticals; Eclipse Aesthetics

Completed

Microneedling Plus the Universal Peel For Acne Scarring

Acne Scarring

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Chronic HBV Infection

United States, Canada
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-938 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Presumptive NAFLD

United States
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III)

Pain | Advanced Cancer

United States, Germany, United Kingdom, Mexico, Poland, Romania, Bulgaria, Czechia, Hungary, Puerto Rico
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections (IGNITE1)

Complicated Intra-abdominal Infections

United States, France, Ukraine, Argentina, Bulgaria, Romania, South Africa, Germany, Estonia, Russian Federation, Lithuania, Czechia, Latvia
Tetraphase Pharmaceuticals, Inc.

Completed

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Complicated Intra-abdominal Infection

United States, Latvia, Lithuania, Romania, India, Bulgaria
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections (IGNITE4)

Complicated Appendicitis | Complicated Intra-abdominal Infections

Ukraine, United States, Bulgaria, Romania, Estonia, Russian Federation, Lithuania, Hungary, Latvia, Georgia, Czechia
Tetraphase Pharmaceuticals, Inc.

Completed

A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization

Normal Healthy Subjects
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Pain | Advanced Cancer

Israel, Italy, Taiwan, United Kingdom, Bulgaria, Hungary, India, Australia, Lithuania, Poland, Spain, Romania, Germany
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Pain | Advanced Cancer

Italy, United States, Taiwan, United Kingdom, Czechia, Bulgaria, Belgium, Latvia, Mexico, Lithuania, Poland, Romania, Hungary, Spain, Israel, Germany, Puerto Rico, Australia
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States

Clinical Trials Sponsored by Topix Pharmaceuticals, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations